2. 您的位置
3. 首页
4. 会议论文
5. Development Strategies of Anti-PD-1 mAb for Tumor Therapeutics in China for Global Market

Development Strategies of Anti-PD-1 mAb for Tumor Therapeutics in China for Global Market

来源 :亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018) | 被引量 : 0次 | 上传用户：acdd5230351

【摘 要】

：

Lower-incidence tumor types are expected to account for ＞50％ of sales by 2020Product life cycle has shortened by almost fivefold from HER2 to now

【作 者】

：

Joe Zhou 

【机 构】

：

Genor Biopharma

【出 处】

：

亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018)

【发表日期】

：

2018年4期

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Lower-incidence tumor types are expected to account for ＞50％ of sales by 2020Product life cycle has shortened by almost fivefold from HER2 to now

其他文献

The recent trend of population analysis for pediatric using allometric scaling and physiological sca

The pharmacokinetic(PK) of drugs and its parameters are different among pediatrics, children and adults due to physiological differences such as body size, maturation of organs.Since population pharma

会议

Pediatric population modelingAllometric scalingPhysiological scaling

Population pharmacokinetic pharmacodynamics model for PEGylated human growth hormone in healthy subj

Background: Growth hormone deficiency (GHD) in paediatric and adult patients so currently necessitates long-term treatment and persistence with a daily s.c injection regimen.Taking the low compliance

会议

Pharmacokinetic/Pharmacodynamic Modeling: Effect of Ibutilide on the QTcF Interval in Healthy Male S

Background: Ibutilide, a class Ⅲ antiarrhythmic agent, is primarily used for conversion of atrial flutter and fibrillation and is a good alternative to electrical cardioversion.However, ibutilide incr

会议

pharmacokineticibutilideEmax model

Selecting the target dose for phase Ⅱ clinical test of new drug using population approach of pre-cli

Introduction and purpose: Influenza viruses can show resistance to anti-viral drugs.This can result from over-use of these drugs and also due to the ability of influenza virus to mutate rapidly.For th

会议

Influenza virusphase Ⅱ clinical trialNONMEMsimulationWinNolin

Application of Physiologically Based Pharmacokinetic Modeling in Apatinib Clinical Pharmacokinetic S

Outlines · Introduction · In vitro ADME Properties · PBPK Modeling · Clinical PK of Apatinib in Healthy Volunteers · Prediction of Food Effect on Apatinib PK and DDIs using PBPK Model Introduction · A

会议

The effect of poor compliance on the pharmacokinetics of valproic acid in children with epilepsy usi

Objective: To investigate the effects of delayed and missed doses(poor compliance) on the pharmacokinetics of valproic acid(VPA) in epileptic children using Monte Carlo simulation.Methods: VPA time-co

会议

Predictions about probabilities of adverse events and appropriate dose of roflumilast for Chinese CO

Backgrounds: Roflumilast is an oral inhibitor of phosphodiesterase 4(PDE4), which is mainly metabolized by CYP3A4 and CYP1A2.The main metabolite of it is roflumilast N-oxide, which contributes to the

会议

Optimizing dosage regimens of piperacillin/tazobactam based on population pharmacokinetic and pharma

Background Piperacillin/tazobactam is an extended-spectrum β-lactamase inhibitor combination antibiotic and is commonly recommended as a first-line therapy for severe bacterial infections.As a time-de

会议

Effect of Target-Mediated Drug Disposition on CPRC3 Pharmacokinetics and Pharmacodynamics in Healthy

Background: The prevalence of diabetes mellitus (DM) dramatically increased over the past decades.Dipeptidyl peptidase Ⅳ (DPP-4) inhibitors are a relatively new group of anti-diabetic agents.CPRC3 is

会议

DPP-4 inhibitorCPRC3pharmacokineticstarget-mediated drug disposition model

Combining “Bottom-up” and “Top-down” methods to assess ethnic difference in clearance of bitopertin

Outline ·Background and Objectives · Methods ·Results ·Discussion ·Conclusions Background-Bitopertin ·Bitopertin is a glycine reuptake inhibitor that is postulated to improve NMDA receptor hypofunctio

会议